A new chapter in cystinosis research has begun. Novartis has officially opened the next phase of its CYStem Phase...
Read moreBy Cystinosis Research Network
April 6, 2025
For our families using Cystadrops, we received the following information from Recordati. This update was in response to direct...
Read moreBy Cystinosis Research Network
April 4, 2025
Novartis has announced the Phase I/II CYStem clinical trial will recruit children ages 2-5 with nephropathic cystinosis. The trial...
Read moreBy Cystinosis Research Network
April 4, 2025
A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal...
Read moreThe Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...
Read moreNews from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...
Read moreThe next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read more